VivoSeq
Oncology

Wilms Tumor

16

Pipeline Programs↗

5

Active Trials↗

11

Companies Involved↗

Wilms tumor is an emerging landscape with 16 programs across 11 companies. The most active players are Bristol-Myers Squibb, Amgen, Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). 1 therapy is approved with 8 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

0/100

Mech. Concentration

18/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2Amgen logo

Amgen

1 program

Phase 2C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 2K

Karyopharm Therapeutics Inc

1 program

Phase 2A

Avyxa

2 programs

Phase 3G

Gynecologic Oncology Group

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

14 of 16 classified programs — the dominant modality here.

13%ALL OTHERSProtein / enzyme213%

Small molecule leads; the ring shows all 16 classified programs, each share of the total. Modality classified for 100% of 17 pipeline programs.

Analysis

Trial Status

6

clinical trials

Recruiting3 · 50%
Active, not recruiting2 · 33%
Completed1 · 17%

Clinical Trials

Trial Activity

6 trials

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05985161·45 enrolled
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Recruiting·Children's Oncology Group·Phase 3·NCT06401330·1,656 enrolled
Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)
Recruiting·CCentre Oscar Lambret·Phase 1/2·NCT05384821·28 enrolled
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
Active, not recruiting·Children's Oncology Group·Phase 3·NCT00945009·249 enrolled
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT02867592·109 enrolled
A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor
Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT00187031·37 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)